Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin as Adjunctive to Insulin in Type 1 Diabetes (EASE-2)
NCT02414958Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of empagliflozin in type 1 diabetes mellitus (T1D), sponsored by Boehringer Ingelheim. Started Jun 2015; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02414958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02414958.